Radar-CNS

Remote Assessment of Disease and Relapse – Central Nervous System

RADAR-CNS is a research programme supported by the Innovative Medicines Initiative (IMI) that will use smart phones and innovative technology in an observational study to establish the potential for wearable devices to make meaningful improvements to the wellbeing of people with a diagnosis of epilepsy, multiple sclerosis or depression. The objective of the programme, in which Epilepsy Alliance Europe is a member of its Patient Advisory Board (through IBE), is to develop new ways of monitoring these three major disorder areas.

RADAR-CNS aims to improve patients’ quality of life and, potentially, to change how these and other chronic disorders are treated.

RADAR - CNS - Epilepsy Alliance Europe
Radar CNS - Epilepsy Programmes in Europe - Epilepsy Alliance Europe

Remote assessment using smartphones and wearable devices can provide a complete picture of a patient’s condition at a level of detail that has not be possible before now. It might also allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.

RADAR-CNS is jointly led by King’s College London and Janssen Pharmaceutica NV, funded by the Innovative Medicines Initiative (IMI) and includes 24 organisations from across Europe and the US. The programme brings together experts from diverse fields including clinical research, engineering, computer science, information technology, data analytics and health services.

Epilepsy, depression, and multiple sclerosis are distinct disorders, with different causes and symptoms, all of which can be severely detrimental to patients’ quality of life and life expectancy. For all three disorders, patients often experience periods where their symptoms are manageable, followed by periods of deterioration and acute illness (relapse). Patient surveys have repeatedly highlighted the need to predict when relapses will happen and to improve the treatments that are available to stop them from occurring.

RADAR-CNS Methods and Means

According to co-lead of the RADAR-CNS programme, Matthew Hotopf, Professor of General Hospital Psychiatry at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London, UK.

Matthew Hotopf - Co-lead of the RADAR-CNS Programme

“In recent years, the quality and quantity of data that we can collect using wearable devices and smartphones has exploded. It may be that this sort of data can improve clinical care simply by providing more accurate information. Better still, it may be possible to spot when a patient is getting into trouble before their clinic visit.”

For example, in depression, someone’s behaviour may change even before they have noticed they are struggling – their sleep may get worse, or they may stop doing so much in the weeks leading up to a relapse. RADAR-CNS will exploit the huge potential of wearable technologies to improve the lives of the millions of people worldwide with chronic illnesses like epilepsy, depression and multiple sclerosis.

Patient Led Research – RADAR-CNS

What is most significant is that patients, from a number of countries in Europe, will be involved in RADAR-CNS from the start, helping to identify the most important symptoms to target. They will also advise researchers on how best to implement remote measurement technologies in a way that is acceptable and engaging to patients, including accounting for privacy and security. It is expected that up to one thousand patients across the three disorder areas will take part in the programme, providing vital input from the best source of information – the patient him- or her-self.

What is most significant is that patients, from a number of countries in Europe, will be involved in RADAR-CNS from the start, helping to identify the most important symptoms to target. They will also advise researchers on how best to implement remote measurement technologies in a way that is acceptable and engaging to patients, including accounting for privacy and security. It is expected that up to one thousand patients across the three disorder areas will take part in the programme, providing vital input from the best source of information – the patient him- or her-self.

Wherever possible, RADAR-CNS will use inexpensive and widely available technology, so that the end results can be made available to as many patients as possible. The research will also be developed in a way that allows the results to be transferred to other diseases, potentially allowing the benefits of remote measurement technologies to become pervasive in medicine, and transforming the way we think about prevention and cure.

Comments From RADAR-CNS Co Lead

According to co-lead of the RADAR-CNS programme Vaibhav Narayan, PhD, Head of Integrated Solutions and Informatics, Neuroscience, Janssen Research & Development, LLC, an affiliate of Janssen Pharmaceutica,

“Our goal is to improve clinical care and outcomes by using data generated by patients as they go about their daily lives to predict and pre-empt relapses and improve their quality of life. Such ‘predictive medicine’ solutions will be backed by scientific evidence and will meet regulatory standards. At the same time, the privacy and security of patients and their care-givers will be fully protected.”

Vaibhav Narayan - RADAR CNS Co-lead

RADAR-CNS Team

Running to 2021, RADAR-CNS is an example of new wave healthcare innovation – using the expertise of clinical researchers, engineers, computer scientists, data analysts and patients to forge the way forward.

The Kick Off Meeting took place in Brescia, Italy, in June 2016 and the programme is now well underway.

http://www.radar-cns.org

http://www.imi.europa.eu/content/radar-cns

RADAR-CNS Team - Epilepsy Alliance Europe

RADAR-CNS Participants

efpia - RADAR CNS Partner
biogen idec - RADAR CNS Participant
Lundbeck - RADAR CNS Participant
janssen - RADAR CNS Participant
MSD - RADAR CNS Participant
ucb Pharma - RADAR CNS Participant

Universities, Research Organisations, Public Bodies & Non-Profit

  • King’s College London
  • Provincia Lombardo-Veneta – Ordine Ospedaliero di San Giovanni di Dio— Fatebenefratelli
  • Lygature
  • Università Vita-Salute San Raffaele
  • Fundacio Hospital Universitari Vall D’Hebron – Institut de Recerca
  • University of Nottingham
  • Centro de Investigacion Biomedica en Red
  • Software AG
  • Region Hovedstaden
  • Stichting Vumc
  • University Hospital, Freiburg
  • Stichting IMEC Nederland
  • Katholieke Universiteit Leuven
  • Northwestern University
  • Universität Passau
  • Università degli Studi di Bergamo
  • Charité – Universitätsmedizin Berlin
  • Intel Corporation (UK) Ltd
  • Janssen Pharmaceutica NV
  • Biogen Idec Limited
  • H. Lundbeck A/S
  • UCB Biopharma SPRL
  • MSD IT Global Innovation Center

SMEs Supporting RADAR-CNS

  • GABO:mi Gesellschaft fur Ablauforganisation:Milliarium MBH & CO KG, Germany
  • The Hyve B.V., Netherlands

Funding Support

RADAR-CNS receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Looking for a partner for your next epilepsy project? Contact the experts!